Pharma companies with ESG more valuable say investors
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Multiples is the first private equity (PE) investor in the company
Following the successful completion of the 7day BVLOS trials, Skye Air targets to undertake approximately 80 flights, each carrying blood samples and medicines for Aster Clinics
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
The company also raised Rs 270 crore investment from Temasek in 2019
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
ABDM is a critical integration that leverages an open, interoperable, standards-based digital system that is secure, and maintains confidentiality and privacy of health-related personal information
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
Subscribe To Our Newsletter & Stay Updated